Bio-Gene Technology (ASX:BGT)

Capital raised to fund commercialisation, accelerate registration, and increase product efficacy.

Henslow has supported Bio-Gene over the past five years on several capital raisings, as their corporate advisor. We have assisted the company from initial seed capital, early-stage funding, pre-IPO, IPO and secondary market placements.

A seamless blend of nature and technology to create one, novel solution.

Bio-Gene is an Australian agricultural technology development company whose technology platform is based on a naturally occurring class of plant compounds known as beta-triketones. Their breakthrough will help provide new solutions for pest control across multiple platforms such as the public health sector, crop protection, grain storage, animal health and in the future, consumer households. These plant compounds have demonstrated insecticidal activity that can help address global issues like insecticide resistance and toxicity.

The Highlights

  • $13.8m

    total raised since 2015

  • $2.4m

    recently raised via private placement

  • $0.4m

    recently raised via share purchase plan offer

Solutions that ingrain nature to its very core

As long-term partners of Bio-Gene, Henslow is proud to continue to help strengthen the company's development, from the ground-up. We look forward to building on this strong foundation.


July 2015

Early Stage $0.275m

March 2016

Early Stage $0.35m

December 2016

Early Stage $1.0m

June 2017

Pre-IPO $2.7m

November 2017

IPO $7.1m

May 2020

Placement $2.4m

June 2020

SPP $0.4m

I am delighted to have successfully raised these funds which will underpin the execution of our commercialisation strategy. The support from both existing and new investors represents further validation of both our technology and strategy.

Richard Jagger, CEO and Managing Director of Bio-Gene Technology